SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Ann Richards — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAnn Richards
Date of birth1933-09-01
IdentifiersMRN HR-ML019-SYN-TD; SSN (made up) 000-19-3381
Document date1997-05-12
AuthorRosalind Teague, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month bone health review before the first zoledronic acid infusion. [S]

History of Present Illness

Ms. Richards returns three months after intake. She has taken vitamin D3 1971 units every day and keeps her calcium at about 1200 mg a day from food. She collected the 24-hour urine sample over the weekend, and the result came back this morning with her blood tests. Her routine dental examination three weeks ago found no problems and no dental work is planned. She finished all 16 sessions of the balance and strength program four days ago and now does the home program three times a week. She has had no falls. She has had no alcohol. She has read about the infusion and asked about the flu-like reaction that can follow a first dose. [S]

ElementDetail
Vitamin DD3 1971 units daily, no missed doses
Dental statusRoutine examination three weeks ago; no work planned
Balance program16 of 16 sessions; home program three times a week
FallsNone
RecoveryNo alcohol; no cravings

Review of Systems

SystemResultFinding
MusculoskeletalNegativeNo bone, back, or thigh pain
GenitourinaryNegativeNo kidney stones or urinary symptoms
ConstitutionalNegativeNo fever or recent illness; drinking plenty of fluid today
PsychiatricNegativeMood good; no cravings; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet dailyOne tablet by mouth dailyOral route1997-02-10activeS
Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 monthsOnce every 12 months, given in the clinic infusion room after a calcium and creatinine checkIntravenous route1997-05-12activeS
Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day)Two tablets every 6 hours as needed for up to three days after the infusionOral route1997-05-12 to 1997-05-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1997-05-12Body height164cmS
1997-05-12Body weight66.4kgS
1997-05-12Body mass index (BMI) [Ratio]24.7kg/m2S
1997-05-12Systolic blood pressure120mm[Hg]S
1997-05-12Diastolic blood pressure74mm[Hg]S
1997-05-12Heart rate72/minS
1997-05-12Respiratory rate14/minS
1997-05-12Body temperature36.6CelS
1997-05-12Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1997-05-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mLTarget 30 ng/mL or higher before and during osteoporosis treatmentNormalS
1997-05-12Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
1997-05-12Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1 mg/dLNormalS
1997-05-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1992)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1997-05-12Calcium [Mass/time] in 24 hour Urine172mg/(24.h)100-300 mg/(24.h)NormalS

Physical Exam

Vital signs recorded on 1997-05-12; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 66.4 kg
MouthGood dentition; no exposed bone
Gait and balanceTimed Up and Go 9 seconds; tandem stance 18 seconds
SpineNo tenderness or kyphosis

Problems

ProblemClinical statusVerificationCodeProvenance
Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 1991 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold)activeconfirmed M85.89S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture.
Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol sinceactiveconfirmed F10.21S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit.
History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls sinceactiveconfirmed Z91.81S — Synthetic modern entry linked to her publicly described falls and fractures.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Laboratory25-hydroxyvitamin DAt baseline; after repletion until 30 ng/mL or more; then yearlyCompleted today38 ng/mL, up from 24; at target; next yearly
LaboratorySerum calcium before each intravenous antiresorptive doseBefore each zoledronic acid doseCompleted today9.5 mg/dL, normal; infusion given
LaboratoryCreatinine and eGFR before each zoledronic acid doseBefore each dose; do not give if creatinine clearance is below 35 mL/minCompleted todayCreatinine 0.8 mg/dL, eGFR 81
Laboratory24-hour urine calciumAt diagnosis, before starting therapyCompleted today172 mg in 24 hours, normal; no hypercalciuria. Deviation: collected about three months after it was ordered, because the sample was missed before the four-week visit. No harm resulted: no drug was started until it was done, and the result is normal. Corrective action: baseline tests that need a home collection are now scheduled with the patient before she leaves the intake visit
LaboratoryBone-turnover marker (fasting serum CTX)Baseline, then 3 to 6 months after starting or changing therapyDueBaseline 560 pg/mL; repeat at the six-month visit, three months after today's dose
Medication safetyDental examination before an antiresorptiveBefore starting a bisphosphonate or denosumabCompleted todayRoutine examination three weeks ago with no problems; no invasive dental work planned
Medication safetyFirst zoledronic acid doseYearlyCompleted today5 mg intravenously over 30 minutes; acetaminophen plan given for the acute-phase reaction
ImagingCentral DXA of the spine and hipEvery 1 to 2 years on therapy until stable, on the same scannerUp to dateRepeat two years after starting therapy
ExaminationStanding height by stadiometerYearly; vertebral imaging again if height falls 2 cm or moreUp to date164.0 cm at intake; unchanged on today's vital signs
ExaminationFall-risk screenYearly, and with any fallCompleted todayAfter the balance program: Timed Up and Go 9 seconds, tandem stance 18 seconds; no falls
SurveyCalcium intake assessmentAt baseline and yearlyUp to dateAbout 1200 mg a day from food
Medication safetyDrug-holiday eligibilityAfter 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonateNot indicatedFirst dose today; reassess after the third yearly dose
Self-managementBalance and strength exercise programWith a history of falls or impaired balanceCompleted today16 of 16 sessions finished four days ago; home program three times a week
Self-managementRecovery check (alcohol, cravings, stress)Every visitCompleted todayNo alcohol; no cravings
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Zoledronic acid infusion today. Call the clinic for fever lasting more than three days, muscle cramps or tingling, or jaw pain. Six-month bone health review in three months with fasting CTX and calcium. Next scheduled visit 1997-08-11: six-month bone health review, three months after the first infusion. [S]